AU2012323032A1 - Regulation of receptor expression through delivery of artificial transcription factors - Google Patents

Regulation of receptor expression through delivery of artificial transcription factors Download PDF

Info

Publication number
AU2012323032A1
AU2012323032A1 AU2012323032A AU2012323032A AU2012323032A1 AU 2012323032 A1 AU2012323032 A1 AU 2012323032A1 AU 2012323032 A AU2012323032 A AU 2012323032A AU 2012323032 A AU2012323032 A AU 2012323032A AU 2012323032 A1 AU2012323032 A1 AU 2012323032A1
Authority
AU
Australia
Prior art keywords
seq
artificial transcription
transcription factor
receptor
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012323032A
Other languages
English (en)
Inventor
Josef Flammer
Alice Huxley
Albert NEUTZNER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ALIOPHTHA AG
Original Assignee
ALIOPHTHA AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ALIOPHTHA AG filed Critical ALIOPHTHA AG
Publication of AU2012323032A1 publication Critical patent/AU2012323032A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/02Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/70Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C07K2319/81Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AU2012323032A 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors Abandoned AU2012323032A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11184706 2011-10-11
EP11184706.7 2011-10-11
PCT/EP2012/069981 WO2013053719A2 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Publications (1)

Publication Number Publication Date
AU2012323032A1 true AU2012323032A1 (en) 2014-04-03

Family

ID=47045011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012323032A Abandoned AU2012323032A1 (en) 2011-10-11 2012-10-10 Regulation of receptor expression through delivery of artificial transcription factors

Country Status (21)

Country Link
US (1) US20140296129A1 (https=)
EP (1) EP2766484A2 (https=)
JP (1) JP2014530607A (https=)
KR (1) KR20140079780A (https=)
CN (1) CN103998609A (https=)
AU (1) AU2012323032A1 (https=)
BR (1) BR112014008456A2 (https=)
CA (1) CA2851560A1 (https=)
CL (1) CL2014000897A1 (https=)
CO (1) CO6930308A2 (https=)
EA (1) EA201490531A1 (https=)
HK (1) HK1197083A1 (https=)
IL (1) IL231865A0 (https=)
IN (1) IN2014CN02586A (https=)
MA (1) MA36970A1 (https=)
MX (1) MX2014004331A (https=)
PH (1) PH12014500786A1 (https=)
SG (1) SG11201400701WA (https=)
TN (1) TN2014000117A1 (https=)
WO (1) WO2013053719A2 (https=)
ZA (1) ZA201401960B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7242180B2 (ja) 2014-09-07 2023-03-20 セレクタ バイオサイエンシーズ インコーポレーテッド 抗ウイルス導入ベクター免疫応答を減弱化するための方法および組成物
BR112020007157A2 (pt) 2017-10-13 2020-09-24 Selecta Biosciences, Inc. métodos e composições para a atenuação de respostas de igm antivetor de transferência viral
WO2019195285A1 (en) * 2018-04-02 2019-10-10 University Of Miami Ifn-beta reporter system for immortalized primary cells
CN114206396A (zh) 2019-05-28 2022-03-18 西莱克塔生物科技公司 用于减弱抗病毒转移载体免疫应答的方法和组合物
EP4075980B1 (en) 2019-12-18 2025-07-23 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use
CN111304314B (zh) * 2020-02-25 2020-11-20 四川省人民医院 Znf124基因在视网膜色素变性疾病早期筛查或辅助诊断中的应用
US20220049310A1 (en) * 2020-02-25 2022-02-17 Sichuan Provincial People's Hospital Use of ZNF124 Gene in Early Screening or Auxiliary Diagnosis of Retinitis Pigmentosa Disease
US11897888B1 (en) 2020-04-30 2024-02-13 Stinginn Llc Small molecular inhibitors of sting signaling compositions and methods of use
US20230141563A1 (en) 2021-10-12 2023-05-11 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector igm responses
WO2023172624A1 (en) 2022-03-09 2023-09-14 Selecta Biosciences, Inc. Immunosuppressants in combination with anti-igm agents and related dosing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE39229E1 (en) * 1994-08-20 2006-08-08 Gendaq Limited Binding proteins for recognition of DNA
US6534261B1 (en) * 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
AU2964101A (en) * 2000-01-21 2001-07-31 Scripps Research Institute, The Methods and compositions to modulate expression in plants
US20020061512A1 (en) * 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
NZ527476A (en) * 2001-02-21 2006-06-30 Novartis Ag Zinc finger binding domains for nucleotide sequence ANN
US20030077279A1 (en) * 2001-10-24 2003-04-24 Cedars-Sinai Medical Center Methods for treating vascular disease by inhibiting toll-like receptor-4
US20060094676A1 (en) * 2004-10-29 2006-05-04 Ronit Lahav Compositions and methods for treating cancer using compositions comprising an inhibitor of endothelin receptor activity
WO2007041218A2 (en) * 2005-09-30 2007-04-12 Oklahoma Medical Research Foundation Regulation of tool-like receptors on stem cells
WO2008140538A1 (en) * 2006-10-04 2008-11-20 Verenium Corporation Dna display screen for expression product with desired binding properties
GB0620705D0 (en) * 2006-10-18 2006-11-29 Opsona Therapeutics Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
CN101333251A (zh) * 2008-01-30 2008-12-31 中国人民解放军第三军医大学 能启动a20基因表达的人工锌指蛋白转录因子及用途
US20110318830A1 (en) * 2008-11-12 2011-12-29 The Regents Of The University Of California Compositions and methods for re-programming and re-differentiating cells
JP2012521766A (ja) * 2009-03-27 2012-09-20 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸(siNA)を用いた高親和性IgE受容体α鎖(FCεR1α)遺伝子発現のRNA干渉媒介性阻害
EP2509594A1 (en) * 2009-12-09 2012-10-17 INSERM - Institut National de la Santé et de la Recherche Médicale Endothelin inhibitors for the treatment of rapidly progressive glomerulonephritis

Also Published As

Publication number Publication date
SG11201400701WA (en) 2014-08-28
EA201490531A1 (ru) 2014-08-29
WO2013053719A2 (en) 2013-04-18
HK1197083A1 (en) 2015-01-02
BR112014008456A2 (pt) 2017-04-11
CL2014000897A1 (es) 2014-11-21
CN103998609A (zh) 2014-08-20
TN2014000117A1 (en) 2015-07-01
KR20140079780A (ko) 2014-06-27
US20140296129A1 (en) 2014-10-02
IL231865A0 (en) 2014-05-28
WO2013053719A3 (en) 2013-06-27
EP2766484A2 (en) 2014-08-20
CO6930308A2 (es) 2014-04-28
MX2014004331A (es) 2014-11-26
CA2851560A1 (en) 2013-04-18
MA36970A1 (fr) 2016-03-31
PH12014500786A1 (en) 2021-08-09
ZA201401960B (en) 2015-06-24
IN2014CN02586A (https=) 2015-08-07
JP2014530607A (ja) 2014-11-20

Similar Documents

Publication Publication Date Title
US20140296129A1 (en) Regulation of receptor expression through delivery of artificial transcription factors
US20160046682A1 (en) Artificial transcription factors engineered to overcome endosomal entrapment
WO2016050934A1 (en) Endosomal disentanglement of artificial transcription factors
CA2543257C (en) Methods and compositions for delivering polynucleotides
CN1330713A (zh) 用于gnn的锌指结合结构域
EP1546322B1 (en) Transposon-based vectors and methods of nucleic acid integration
EP1631676A2 (en) Transducible dna-binding proteins
US20160046681A1 (en) Artificial transcription factors regulating nuclear receptors and their therapeutic use
US20050032186A1 (en) Regulatory zinc finger proteins
JP2004520054A (ja) ヌクレオチド配列annについての亜鉛フィンガー結合ドメイン
AU2014247131A1 (en) Artificial transcription factors for the treatment of diseases caused by OPA1
WO2022109058A1 (en) Nucleases comprising cell penetrating peptide sequences
CN101081870B (zh) 一种抗肿瘤生物药物PTD4-GFP-Apoptin融合蛋白及其制备方法
US20180066241A1 (en) Pro-apoptotic set and pp2a peptides
TW201736394A (zh) 人造轉錄因子之內體解糾纏
EP1605964B1 (en) TARGETED PROTEIN DEGRADATION VEHICLES (TPDVs), NUCLEIC ACID CONSTRUCTS ENCODING THEM AND THEIR USE
US20160039892A1 (en) Artificial transcription factors and their use for the treatment of maladapted wound healing in the eye
Ho Structure-function analysis of the MAT [Alpha] 2 protein of Saccharomyces cerevisiae
Zhong Transcriptional regulation by the yeast homeodomain Mat alpha2 protein in combination with Mcm1
WO2008043241A1 (fr) Protéine de fusion portant une neurotrophine sur la barrière sang-cerveau, gène codant et utilisation de ladite protéine

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period